Please upgrade your browser.
Lancet reported objective response rate of greater than forty percent.
Side Effects of Sunitinib in Kidney Cancer Are 2 to 3 Times More Expensive to Manage Than Those of Avastin Plus Interferon
The Avastin-based therapy patient benefit is comparable in terms of PFS to sunitinib, but the treatment regimens have very different side effect profiles.
"The positive Phase 1 data we presented last month at AACR, coupled with the high investigator and patient interest in this Phase 2 trial, suggests a significant market opportunity for a differentiated VEGF receptor inhibitor. Based on our promising, early data, we believe the unique triple VEGF receptor inhibition and tolerability positions AV-951 as a potential best-in-class anti-angiogenic agent."
The only renal cancer therapy proven to extend median overall survival compared with interferon-alpha in patients with advanced renal cell carcinoma (RCC).
In patients with advanced renal cell cancer, there was an overall response rate of 35 percent.
Drug firms Wyeth and Novartis AG each reported new uses for their respective cancer drugs at a medical conference Saturday.
When Richard Eckley was diagnosed with kidney cancer, doctors offered him an unenviable choice.
In renal cell and prostate cancer HIF-1α is degraded by Geldanamycin in both normoxia and hypoxia.
Dr. Robert Uzzo argued for observation in many renal masses.
In the future, kidney cancer is likely to be managed as a chronic disease.
|Powered by NeonCRM|